P W Armstrong Selected Research

P W Armstrong Research Topics

Disease

14	Myocardial Infarction 03/2005 - 01/2000
11	Acute Coronary Syndrome 07/2005 - 06/2000
7	Heart Failure 01/2020 - 06/2000
7	ST Elevation Myocardial Infarction 08/2009 - 09/2001
6	Infarction (Infarctions) 07/2002 - 04/2000
4	Hemorrhage 03/2005 - 08/2000
3	Ischemia 03/2005 - 10/2000
2	Shock 08/2009 - 01/2000
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2003 - 08/2000
2	Unstable Angina 07/2002 - 06/2000
2	Coronary Disease (Coronary Heart Disease) 10/2001 - 04/2001
1	Frailty 01/2020
1	Hemorrhagic Fever with Renal Syndrome (HFRS) 01/2020
1	Dyspnea (Shortness of Breath) 07/2011
1	Chest Pain (Chest Pains) 09/2003
1	Non-ST Elevated Myocardial Infarction 07/2002
1	Body Weight (Weight, Body) 12/2001
1	Thrombosis (Thrombus) 03/2001
1	Hyperkalemia 01/2001
1	Hypotension (Low Blood Pressure) 01/2001
1	Diabetes Mellitus 12/2000
1	Atherosclerosis 08/2000
1	Thrombocytopenia (Thrombopenia) 08/2000
1	Sudden Death 08/2000
1	Disease Progression 07/2000
1	Heart Rupture 04/2000
1	Cicatrix (Scar) 04/2000
1	Dyslipidemias (Dyslipidemia) 04/2000
1	Hypertension (High Blood Pressure) 04/2000
1	Heart Arrest (Cardiac Arrest) 03/2000
1	Cardiogenic Shock 01/2000

Drug/Important Bio-Agent (IBA)

5	Tissue Plasminogen Activator (Alteplase)FDA Link 09/2003 - 01/2000
4	Pharmaceutical PreparationsIBA 03/2005 - 08/2000
4	Heparin (Liquaemin)FDA LinkGeneric 03/2005 - 03/2001
4	Streptokinase FDA Link 10/2000 - 03/2000
3	paragonIBA 07/2005 - 06/2001
3	Lisinopril (Prinivil)FDA LinkGeneric 12/2000 - 08/2000
2	(2S)- 2- (4- (((3S)- 1- acetimidoyl- 3- pyrrolidinyl)oxy)phenyl)- 3- (7- amidino- 2- naphtyl)propanoic acidIBA 03/2005 - 02/2004
2	Glycoproteins (Glycoprotein)IBA 10/2003 - 06/2001
2	Staphylococcus aureus auR protein (staphylokinase)IBA 09/2003 - 05/2000
2	Tenecteplase FDA Link 07/2003 - 12/2001
2	Eptifibatide (Integrilin)FDA Link 07/2002 - 06/2000
2	HirudinsIBA 12/2001 - 03/2001
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2001 - 12/2000
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2001 - 12/2000
2	Platelet Membrane GlycoproteinsIBA 08/2000 - 06/2000
1	Brain Natriuretic Peptide (Natrecor)FDA Link 07/2011
1	Blood Glucose (Blood Sugar)IBA 08/2009
1	Factor Xa InhibitorsIBA 03/2005
1	Factor Xa (Coagulation Factor Xa)IBA 03/2005
1	Creatine Kinase (Creatine Phosphokinase)IBA 02/2004
1	MB Form Creatine KinaseIBA 02/2004
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 07/2003
1	Enoxaparin (Lovenox)FDA LinkGeneric 07/2003
1	TNK-tissue plasminogen activatorIBA 12/2001
1	FibrinIBA 12/2001
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2001
1	Indicators and Reagents (Reagents)IBA 11/2001
1	Troponin T (Troponin T1)IBA 06/2001
1	Trinitrotoluene (TNT)IBA 06/2001
1	LipidsIBA 04/2001
1	AntithrombinsIBA 03/2001
1	Thrombin FDA Link 03/2001
1	reteplase FDA Link 10/2000
1	Plasminogen Activators (Plasminogen Activator)IBA 10/2000
1	NitratesIBA 10/2000
1	CalciumIBA 10/2000
1	lotrafibanIBA 08/2000
1	EnzymesIBA 06/2000
1	GlucocorticoidsIBA 04/2000

Therapy/Procedure

8	Therapeutics 07/2011 - 06/2000
4	Percutaneous Coronary Intervention 08/2009 - 12/2001
4	Thrombolytic Therapy 12/2001 - 01/2000
3	Time-to-Treatment 11/2005 - 10/2000
2	Patient Readmission 01/2020 - 07/2011
2	Length of Stay 01/2003 - 10/2000
2	Aftercare (After-Treatment) 12/2001 - 03/2001
2	Secondary Prevention 10/2001 - 08/2000
1	Drug Therapy (Chemotherapy) 01/2020
1	Treatment Delay 11/2005
1	Drug Tapering 01/2001
1	Resuscitation 03/2000